Alternatives to Meperidine for Treating Post-Operative Shivering and Rigors with Amphotericin

Post-operative shivering and rigors associated with amphotericin administration can be uncomfortable and require effective management. While meperidine has been traditionally used, there are other alternatives that can be considered, focusing on safety and efficacy:

1. Non-Pharmacological Methods

• Warming Devices: Use of forced-air warming blankets or other warming technologies can help manage body temperature and reduce shivering.
• Warm IV Fluids: Administering pre-warmed intravenous fluids can prevent heat loss and reduce the occurrence of shivering.

2. Pharmacological Alternatives

• Clonidine: An alpha-2 adrenergic agonist, clonidine can be effective in reducing shivering by modulating central thermoregulation.
• Dexamethasone: A corticosteroid that may help reduce inflammatory responses associated with amphotericin and potentially mitigate rigors.
• Ondansetron: While primarily used as an antiemetic, ondansetron has shown efficacy in reducing shivering in some cases.
• Midazolam: A benzodiazepine that can provide anxiolysis and help reduce shivering through its sedative effects.
• Acetaminophen: Paracetamol can be used for its antipyretic effects to help manage mild cases of shivering.

3. Monitoring and Consultation

It's important for healthcare professionals to monitor patients closely and consider patient-specific factors when selecting an appropriate treatment. Consulting with an anesthesiologist or a specialist in infectious diseases may also provide individualized treatment options.

Always ensure that alternatives are chosen based on patient safety, tolerability, and the clinical context.

Leucovorin for Autism in Pediatric Patients

Evidence

Leucovorin, a folinic acid, has been investigated for its potential benefits in managing symptoms of autism spectrum disorder (ASD). Research into its efficacy is ongoing, with some studies suggesting it may help improve certain behaviors and symptoms in a subset of children with autism, particularly those with an underlying metabolic or genetic disorder affecting folate metabolism.

One study published in 2018 explored the use of high-dose folinic acid in children with ASD. The randomized, double-blind, placebo-controlled study involved children who had folate receptor alpha autoantibodies, which can interfere with folate transport across the blood-brain barrier. It found that treatment with folinic acid improved verbal communication in participants.

Dosing

The dosing of leucovorin for treating autism symptoms in pediatric patients varies based on the study and individual patient needs. In the 2018 study mentioned above, the dosage used was approximately 2 mg/kg per day, up to a maximum of 50 mg per day. However, it's important to note that treatment should be overseen by a healthcare professional familiar with the patient's medical history and specific needs.

It's crucial for parents and caregivers to consult with their child's healthcare provider before starting any new treatment, as leucovorin therapy may not be suitable for all children with autism and should be tailored to the individual.

Conclusion

While some evidence suggests potential benefits of leucovorin in a specific subset of children with ASD, further research is needed to better understand its efficacy and safety. Healthcare professionals should carefully consider the individual characteristics of patients when prescribing leucovorin for autism-related symptoms.

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis

Introduction

Ixekizumab is a monoclonal antibody used for the treatment of moderate-to-severe plaque psoriasis. It works by targeting and neutralizing interleukin-17A (IL-17A), a protein that plays a key role in the inflammatory process of psoriasis.

Efficacy

Clinical trials have demonstrated that Ixekizumab is highly effective in reducing the severity of psoriasis symptoms. Many patients experience significant improvement in skin clearance and quality of life.

Dosage and Administration

Ixekizumab is administered via subcutaneous injection. The initial dosing regimen typically involves an induction phase followed by maintenance dosing.

Side Effects

Common side effects include injection site reactions, upper respiratory tract infections, and nausea. Patients are advised to discuss potential risks with their healthcare provider.

Conclusion

Ixekizumab offers an effective treatment option for patients with moderate-to-severe plaque psoriasis, particularly for those who have not responded to other therapies. Consultation with a healthcare professional is necessary to determine its suitability for individual patients.

Clinical Role of Finerenone in Patients with CKD and Type 2 Diabetes

Background

Chronic kidney disease (CKD) is a common complication in patients with type 2 diabetes, often leading to adverse cardiovascular outcomes and progression to end-stage kidney disease. There is a paramount need for effective therapeutic options to slow disease progression and reduce associated risks.

Introduction to Finerenone

Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It has a unique receptor affinity profile, which differentiates it from other mineralocorticoid receptor antagonists like spironolactone and eplerenone.

Clinical Benefits

• Renal Protection: Finerenone has been shown to reduce the progression of kidney disease in patients with CKD and type 2 diabetes by lowering albuminuria and preserving renal function.
• Cardiovascular Benefits: Clinical trials have demonstrated that finerenone significantly reduces the risk of cardiovascular events, such as heart failure and myocardial infarction, in this patient population.

Mechanism of Action

Finerenone works by blocking harmful effects mediated through the mineralocorticoid receptor. This action helps reduce inflammation and fibrosis, key contributors to kidney damage and cardiovascular disease in diabetes.

Clinical Trials

Finerenone's efficacy and safety have been evaluated in major clinical trials, including:

• FIDELIO-DKD: Showed significant kidney and cardiovascular benefits in patients with CKD and type 2 diabetes.
• FIGARO-DKD: Focused on cardiovascular outcomes, demonstrating a reduction in cardiovascular morbidity and mortality.

Conclusion

Finerenone represents an important advancement in the management of CKD in patients with type 2 diabetes, offering both renal and cardiovascular protection. Its introduction provides a promising option to enhance clinical outcomes in this high-risk group.